A Leader in Clinical Trials Participation.

Our commitment to clinical trials gives Hawaii’s retinal patients access to the latest technological breakthroughs


NeoVista Clinical Trial

Retina Institute of Hawaii Selected To Hold Clinical Trials For Residents Suffering From Wet Age-Related Macular Degeneration


There is new hope for Hawaii residents suffering from wet Age-Related Macular Degeneration (AMD), the leading cause of blindness among the elderly. That’s because the Retina Institute of Hawaii has been selected as one of 26 sites in the United States to hold clinical trials for NeoVista’s Novel Wet AMD Therapy. The clinical trial is now open for qualifying patients.

Current AMD treatment involves monthly visits, where patients receive targeted injections in the infected area. NeoVista’s Novel Wet AMD Therapy offers a more aggressive option for patients, with a one-time treatment of a targeted dose of beta radiation to leaking blood vessels and two injections of anti-vascular endothelial growth factor.

Wet AMD occurs when blood vessels grow underneath the eye’s retina and macula, destroying or distorting vision. As it primarily infects the elderly, it is often difficult for sufferers to frequent their doctor’s office to receive the current standard treatment of monthly injections.

The Retina Institute of Hawaii has already performed a number of the NeoVista Novel Wet AMD procedures on patients with positive results. For more information or to schedule a consultation, please call (808) 955-0255.

About the NeoVista procedure

At present, the standard of care for wet AMD is the intravitreal injection of anti–vascular endothelial growth factor (anti-VEGF) medication. This therapy helps control choroidal neovascularization (CNV) and stabilize vision. Like anti-VEGF therapy, beta radiation therapy affects the abnormal blood vessels of wet AMD by slowing the development of new vessels and reducing inflammation, allowing the macula to return to its normal position. Unlike standard therapy, however, the NeoVista procedure is only performed once, and patients receive only two doses of an anti-VEGF drug.
The treatment being used in the pivotal study utilizes a typical vitrectomy, with radiation delivered using the NeoVista system. Patients usually require only local anesthesia, and the entire procedure normally takes less than 1 hour.
Radiation delivery using the NeoVista device is highly focal, penetrating the target area to a depth of only 3 mm and covering an area slightly larger than 5 mm in diameter. Because beta radiation dissipates very rapidly, surrounding normal tissues are less affected than with other forms of radiation used in older treatments. Thus, application is not only more accurate but more localized. This helps to reduce the risk of radiation-induced toxicity significantly.
The full-body radiation dose received by the patient is less than the dose received during a typical chest x-ray. The surgeon and others in the operating theater also receive minimal exposure.